Animal models of nonalcoholic fatty liver disease

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature Reviews Gastroenterology &Hepatology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrgastro.2010.191PMID 21119613
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.

  2010cited by this paper
• Sfrp5 Is an Anti-Inflammatory Adipokine That Modulates Metabolic Dysfunction in Obesity

  2010cited by this paper
• Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.

  2010cited by this paper
• Recent advances in nonalcoholic fatty liver disease

  2010cited by this paper
• Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.

  2010cited by this paper
• Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease.

  2010cited by this paper
• Patatin‐like phospholipase domain‐containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease

  2010cited by this paper
• Adiponectin deficiency promotes the production of inflammatory mediators while severely exacerbating hepatic injury in mice with polymicrobial sepsis.

  2010cited by this paper
• Nonalcoholic fatty liver disease: pathology and pathogenesis.

  2010cited by this paper
• Improved Insulin Sensitivity in High Fat- and High Cholesterol-fed Ldlr−/− Mice with Macrophage-specific Transgenic Expression of Cholesteryl Ester Hydrolase

  2010cited by this paper
• Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease

  2010cited by this paper
• Patatin‐like phospholipase domain‐containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease

  2010cited by this paper
• Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice.

  2010cited by this paper
• IMPROVED INSULIN SENSITIVITY IN HIGH-FAT HIGH-CHOLESTEROL FED LDLR-/- MICE WITH MACROPHAGE-SPECIFIC TRANSGENIC EXPRESSION OF CHOLESTERYL ESTER HYDROLASE: ROLE OF MACROPHAGE INFLAMMATION AND INFILTRATION INTO ADIPOSE TISSUE

  2010cited by this paper
• Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice.

  2010cited by this paper
• A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits.

  2010cited by this paper
• The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome

  2010cited by this paper
• Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice.

  2010cited by this paper
• A position statement on NAFLD/NASH based on the EASL 2009 special conference.

  2010cited by this paper
• Transgenic expression of cholesterol 7α‐hydroxylase in the liver prevents high‐fat diet–induced obesity and insulin resistance in mice

  2010cited by this paper
• Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease.

  2010cited by this paper
• Recent advances in nonalcoholic fatty liver disease

  2009cited by this paper
• A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis

  2009cited by this paper
• c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice.

  2009cited by this paper
• Adipocyte Apoptosis, a Link between Obesity, Insulin Resistance, and Hepatic Steatosis*

  2009cited by this paper
• CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity

  2009cited by this paper
• VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet‐induced nonalcoholic steatohepatitis model in mice

  2009cited by this paper
• Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis.

  2009cited by this paper
• Adiponectin Promotes Macrophage Polarization toward an Anti-inflammatory Phenotype*

  2009cited by this paper
• Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis

  2009cited by this paper
• Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters

  2009cited by this paper
• Toll‐like receptor 4 is involved in the development of fructose‐induced hepatic steatosis in mice

  2009cited by this paper
• Histopathology of non-alcoholic fatty liver disease.

  2009cited by this paper
• Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive

  2008cited by this paper
• Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent.

  2008cited by this paper
• Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

  2008cited by this paper
• Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

  2008cited by this paper
• A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet.

  2008cited by this paper
• Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.

  2008cited by this paper
• MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes.

  2008cited by this paper
• Hepatic NF-κB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis

  2008cited by this paper
• Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects.

  2008cited by this paper
• Fructose consumption as a risk factor for non-alcoholic fatty liver disease.

  2008cited by this paper
• Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.

  2008cited by this paper
• Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin.

  2008cited by this paper
• Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice

  2008cited by this paper
• Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

  2008cited by this paper
• Toll‐like receptors and adaptor molecules in liver disease: Update

  2008cited by this paper
• Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis

  2008cited by this paper
• Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet

  2008cited by this paper
• Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model.

  2007cited by this paper
• Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma.

  2007cited by this paper
• Pathogenesis of NASH: animal models.

  2007cited by this paper
• Overexpression of apolipoprotein CIII increases and CETP reverses diet-induced obesity in transgenic mice

  2007cited by this paper
• Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies.

  2007cited by this paper
• Obesity induces a phenotypic switch in adipose tissue macrophage polarization.

  2007cited by this paper
• Lipid‐induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet

  2007cited by this paper
• Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARγ agonist pioglitazone

  2007cited by this paper
• Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma

  2007cited by this paper
• Acute disseminated encephalomyelitis: a follow-up study in Taiwan

  2006cited by this paper
• Obesity and the role of adipose tissue in inflammation and metabolism.

  2006cited by this paper
• COX‐2 induction in mice with experimental nutritional steatohepatitis: Role as pro‐inflammatory mediator

  2006cited by this paper
• Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis.

  2006cited by this paper
• Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.

  2006cited by this paper
• High-fat emulsion-induced rat model of nonalcoholic steatohepatitis.

  2006cited by this paper
• Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men

  2006cited by this paper
• Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research

  2006cited by this paper
• Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.

  2006cited by this paper
• Jnk1 but not jnk2 promotes the development of steatohepatitis in mice

  2006cited by this paper
• Hepatocyte CYP2E1 Overexpression and Steatohepatitis Lead to Impaired Hepatic Insulin Signaling*

  2005cited by this paper
• Steatohepatitis induced by intragastric overfeeding in mice

  2005cited by this paper
• Morphology of alcoholic liver disease.

  2005cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.

  2005cited by this paper
• NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis.

  2005cited by this paper
• Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB

  2005cited by this paper
• Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats.

  2005cited by this paper
• The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance.

  2004cited by this paper
• Administration of the potent PPARα agonist, Wy‐14,643, reverses nutritional fibrosis and steatohepatitis in mice

  2004cited by this paper
• Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice.

  2004cited by this paper
• Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway

  2004cited by this paper
• Model of nonalcoholic steatohepatitis.

  2004cited by this paper
• Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production.

  2004cited by this paper
• Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice

  2004cited by this paper
• Cholesterol and Cholate Components of an Atherogenic Diet Induce Distinct Stages of Hepatic Inflammatory Gene Expression*

  2003cited by this paper
• Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

  2003cited by this paper
• Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin.

  2003cited by this paper
• Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis.

  2003cited by this paper
• Central role of PPARα‐dependent hepatic lipid turnover in dietary steatohepatitis in mice

  2003cited by this paper
• Non‐alcoholic steatohepatitis: Definitions and pathogenesis

  2002cited by this paper
• Mallory body—A disease‐associated type of sequestosome

  2002cited by this paper
• A central role for JNK in obesity and insulin resistance

  2002cited by this paper
• CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.

  2000cited by this paper
• Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle.

  2000cited by this paper
• Endogenous liver carcinogenesis in the rat *

  1999cited by this paper
• Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

  1999cited by this paper
• Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

  1999cited by this paper
• Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation.

  1996cited by this paper
• Comparative Changes in the Liver of Female Fischer-344 Rats after Short-Term Feeding of a Semipurified or a Semisynthetic L-Amino Acid-Defined Choline-Deficient Diet

  1995cited by this paper
• Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

  1990cited by this paper

• GCN5 drives MASLD progression through LXRα/SREBP1c signaling pathway-mediated de novo lipogenesis.

  2026cites this paper
• Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights

  2026cites this paper
• Copper deficiency aggravates oxidative stress, inflammation, and liver damage induced by a high-fat diet in a mouse model.

  2026cites this paper
• Dietary Strategies to Modulate Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  2025cites this paper
• Elevated miR-34a induced by lipotoxicity and inflammation mediates pathophysiological communication between hepatocytes and hepatic stellate cells in liver fibrosis

  2025cites this paper
• Advancing hepatotoxicity assessment: current advances and future directions

  2025cites this paper
• ACT001 alleviates MASLD through gut microbiota–bile acid–FXR axis in mice

  2025cites this paper
• Animal models of disease: Achievements and challenges.

  2025cites this paper
• Chitosan and chito-oligosaccharides as multifunctional therapeutics for metabolic dysfunction-associated steatotic liver disease (MASLD).

  2025cites this paper
• Effects of Diet and Exercise on Mitochondrial Health in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Role of Ceramides

  2025cites this paper
• 2,5-Dihydroxybenzoic Acid Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Targeting the CCL2-CCR2 Axis to Reduce Lipid Accumulation

  2025cites this paper
• Synergistic effects of CC chemokine receptor 2 inhibitor and transforming growth factor-β type I receptor kinase inhibitor combination in metabolic dysfunction-associated steatohepatitis.

  2025cites this paper
• RETREG1-mediated reticulophagy is activated by an ATF4-CEBPG/C/EBPγ heterodimer and confers protection against lipotoxicity

  2025cites this paper
• A newly developed model of atherosclerosis caused by the stress of metabolic syndrome in apolipoprotein E knockout mouse

  2025cites this paper
• Engineered Hydrogels for Organoid Models of Human Nonalcoholic Fatty Liver Disease

  2025cites this paper
• A UFD1 variant encoding a microprotein modulates UFD1f and IPMK ubiquitination to play pivotal roles in anti-stress responses

  2025cites this paper
• Carboxylesterase 2A gene knockout or enzyme inhibition alleviates steatohepatitis in rats by regulating PPARγ and endoplasmic reticulum stress.

  2025cites this paper
• Animal models of disease: Achievements and challenges.

  2025cites this paper
• Liver-breast communication of adipocyte-oriented exosomes drives primary mammary cancer progression.

  2025cites this paper
• Protective effect of vitamin D on high-fat-diet-induced metabolic dysfunction-associated steatotic liver disease in mice.

  2025cites this paper
• AMPK‐Dependent Epigenetic Regulation of Metabolism Mediates the Anti‐Cancer Action of Pterostilbene in Hepatocellular Carcinoma

  2025cites this paper
• Non-Alcoholic Fatty Liver Disease in Poultry: Risk Factors, Mechanism of Development, and Emerging Strategies

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes

  2025cites this paper
• Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity

  2025cites this paper
• Lipid Metabolism and Immune Crosstalk in Fish Gut-Liver Axis: Insights from SOCS8 Knockout and Dietary Stress Models.

  2025cites this paper
• Genistein relieves liver damage and improves lipid dysregulation through endoplasmic reticulum suppression in nonalcoholic steatohepatitis rats

  2024cites this paper
• Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective

  2024cites this paper
• Sappanone A alleviates metabolic dysfunction-associated steatohepatitis by decreasing hepatocyte lipotoxicity via targeting Mup3 in mice.

  2024cites this paper
• Time-Restricted Feeding Ameliorates Methionine–Choline Deficient Diet-Induced Steatohepatitis in Mice

  2024cites this paper
• Cascaded fingerprint recognition for non-alcoholic steatohepatitis imaging

  2024cites this paper
• Immunological dynamics in MASH: from landscape analysis to therapeutic intervention

  2024cites this paper
• Choline consumption reduces CVD risk via body composition modification

  2024cites this paper
• Animal models of disease: Achievements and challenges.

  2024cites this paper
• Non‐Invasive Detection of Early‐Stage Fatty Liver Disease via an On‐Skin Impedance Sensor and Attention‐Based Deep Learning

  2024cites this paper
• A metabolic dysfunction-associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system

  2024cites this paper
• Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy

  2024cites this paper
• A Novel TGFβ Receptor Inhibitor, IPW-5371, Prevents Diet-induced Hepatic Steatosis and Insulin Resistance in Irradiated Mice

  2024cites this paper
• NUP85 alleviates lipid metabolism and inflammation by regulating PI3K/AKT signaling pathway in nonalcoholic fatty liver disease

  2024cites this paper
• Transketolase promotes MAFLD by limiting inosine-induced mitochondrial activity.

  2024cites this paper
• Preface.

  2024cites this paper
• Modulation of liver cholesterol homeostasis by choline supplementation during fibrosis resolution

  2024cites this paper
• l-[5-11C]Glutamine PET imaging noninvasively tracks dynamic responses of glutaminolysis in non-alcoholic steatohepatitis

  2024cites this paper
• Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease

  2024cites this paper
• NASH triggers cardiometabolic HFpEF in aging mice

  2024cites this paper
• Normothermic machine perfusion of explanted livers: Exploratory study of an alternative translational model for end-stage liver disease.

  2024cites this paper
• Free fatty acid-induced DDX3 inhibits autophagy via miR-141 upregulation in diet-induced MASLD mice model system.

  2024cites this paper
• 3D culture models to study pathophysiology of steatotic liver disease.

  2024cites this paper
• Dietary milk polar lipids modulate gut barrier integrity and lipid metabolism in C57BL/6J mice during systemic inflammation induced by Escherichia coli lipopolysaccharide.

  2024cites this paper
• Folate Deficiency and/or the Genetic Variant Mthfr677C >T Can Drive Hepatic Fibrosis or Steatosis in Mice, in a Sex-Specific Manner.

  2024cites this paper
• Methanol Leaves Extract of Zingiber officinale (Roscoe) exhibited Anti-Obesity Effect in Wistar Rats Fed with a High Fat Diet

  2023cites this paper
• Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humans.

  2023cites this paper
• Characteristics of contemporary drug clinical trials regarding the treatment of non-alcoholic steatohepatitis.

  2023cites this paper
• Imaging Fibrosis Progression in NASH with an Allysine-Reactive AIE Probe

  2023cites this paper
• Extraction, characterization, and anti-nonalcoholic steatohepatitis activity of a (1,3) (1,6)-β-D-glucan from the Polyporus umbellatus (Pers.) Fries.

  2023cites this paper
• Modelling porcine NAFLD by deletion of leptin and defining the role of AMPK in hepatic fibrosis

  2023cites this paper
• iTRAQ-based quantitative proteomics analysis of the effect of ACT001 on non-alcoholic steatohepatitis in mice

  2023cites this paper
• Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy

  2023cites this paper
• Utility of ultrasonography in a mouse model of non-alcoholic steatohepatitis induced by a choline-deficient, high-fat diet and dextran sulfate sodium

  2023cites this paper
• One-carbon metabolizing enzyme ALDH1L1 influences mitochondrial metabolism through 5-aminoimidazole-4-carboxamide ribonucleotide accumulation and serine depletion, contributing to tumor suppression

  2023cites this paper
• Zanthoxylum bungeanum amides ameliorates nonalcoholic fatty liver via regulating gut microbiota and activating AMPK/Nrf2 signaling.

  2023cites this paper
• Hepatocyte CD36 protects mice from NASH diet-induced liver injury and fibrosis via blocking N1ICD production.

  2023cites this paper
• Experimental models of fatty liver diseases: Status and appraisal

  2023cites this paper
• Thermoneutral housing does not accelerate metabolic dysfunction-associated fatty liver disease in male or female mice fed a Western diet

  2023cites this paper
• Frequencies of Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Lean Individuals

  2023cites this paper
• IL-1β neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH

  2023cites this paper
• Experimental Models for Studying Structural and Functional State of the Pathological Liver (Review)

  2023cites this paper
• The role of ChREBP in carbohydrate sensing and NAFLD development

  2023cites this paper
• Advancements in Research on Constructing Physiological and Pathological Liver Models and Their Applications Utilizing Bioprinting Technology

  2023cites this paper
• Thermoneutral housing does not accelerate metabolic dysfunction-associated fatty liver disease in male or female C57Bl/6J mice fed a Western diet.

  2023cites this paper
• Potential therapeutic effect of medium chain triglyceride oil in ameliorating diabetic liver injury in a streptozotocin-induced diabetic murine model.

  2023cites this paper
• Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies

  2023cites this paper
• Raman imaging of rat nonalcoholic fatty liver tissues reveals distinct biomolecular states

  2023cites this paper
• Myeloperoxidase-Sensitive T1 and T2 Switchable MR Imaging for Diagnosis of Nonalcoholic Steatohepatitis.

  2023cites this paper
• Characterization of hepatic fatty acids using magnetic resonance spectroscopy for the assessment of treatment response to metformin in an eNOS−/− mouse model of metabolic nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

  2023cites this paper
• The loss of hepatic PPARα in mice causes hypertension and cardiovascular disease.

  2023cites this paper
• Therapeutic impact of purified Trichoderma viride l-asparaginase in murine model of liver cancer and in vitro Hep-G2 cell line

  2023cites this paper
• Inhibition of glutathione generation in hepatic steatotic rats augments oxidative stress

  2023cites this paper
• Differences of Lipid Proton Compositions and Fatty Acids Between Alcoholic Fatty Liver and High-Fat Diet Fatty Liver Animal Models: 9.4 T Magnetic Resonance Spectroscopy Study

  2023cites this paper
• A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet

  2022cites this paper
• Application of Disulfiram and its Metabolites in Treatment of Inflammatory Disorders

  2022cites this paper
• Effect of apple vinegar on folliculogenesis and ovarian kisspeptin in a high-fat diet-induced nonalcoholic fatty liver disease in rat

  2022cites this paper
• The protective effect of Capparis spinosa fruit on triptolide-induced acute liver injury: A metabolomics-based systematic study

  2022cites this paper
• P38γ modulates the lipid metabolism in non‐alcoholic fatty liver disease by regulating the JAK–STAT signaling pathway

  2022cites this paper
• Mouse models of nonalcoholic steatohepatitis and their application to new drug development

  2022cites this paper
• Exploring the active compounds and potential mechanism of the anti-nonalcoholic fatty liver disease activity of the fraction from Schisandra chinensis fruit extract fraction based on multi-technology integrated network pharmacology.

  2022cites this paper
• Comparative study between Transversus Abdominus Plain block, local subcutaneous injection in wound and intravenous Nalbuphine in decreasing post-operative pain in cesarean section

  2022cites this paper
• A non-mitogenic FGF4 analog alleviates non-alcoholic steatohepatitis through an AMPK-dependent pathway.

  2022cites this paper
• Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis

  2022cites this paper
• Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention

  2022cites this paper
• Comparison of Non-Alcoholic Fatty Liver Disease (NAFLD) Model using Diet-Induced Nafld Mice with Genetically Modified Mice

  2022cites this paper
• The potential of mecciRNA in hepatic stellate cell to regulate progression of nonalcoholic hepatitis

  2022cites this paper
• The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?

  2022cites this paper
• One Carbon Metabolism and S-Adenosylmethionine in Non-Alcoholic Fatty Liver Disease Pathogenesis and Subtypes

  2022cites this paper
• Advancements in MAFLD Modeling with Human Cell and Organoid Models

  2022cites this paper
• Morphological Changes in Major Salivary Glands in Mice Treated With a Choline and Methionine Deficient Diet

  2022cites this paper
• The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review

  2022cites this paper
• Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease

  2022cites this paper
• Mitigation of MAFLD in High Fat-High Sucrose-Fructose Fed Mice by a Combination of Genistein Consumption and Exercise Training

  2022cites this paper
• Mitochondrial stress induces AREG expression and epigenomic remodeling through c-JUN and YAP-mediated enhancer activation

  2022cites this paper
• Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3

  2022cites this paper